ICER gives thumbs up with caveats for Novartis and Amgen's novel migraine biologic

4 July 2018

Following a draft document released earlier this year, US cost-effectiveness watchdog the Institute for Clinical and Economic Review (ICER) has released its final evidence report on three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks.

The products under review are Amgen (Nasdaq: AMGN) and Novartis’ (NOVN: VX) Aimovig (erenumab), Teva Pharmaceutical Industries’ (NYSE: TEVA) fremanezumab, and Eli Lilly’s (NYSE: LLY) galcanezumab.

ICER, a non-profit with links to the insurance industry, has previously found that “evidence was adequate to demonstrate a net health benefit of the CGRP inhibitors for individuals with chronic migraine and no other available treatment options.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK